SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A bullish Morgan Stanley call and SpaceXs proposed Florida methane pipeline for Starship are driving attention, with traders also focused on an upcoming Starship flight and the companys AI ambitions. Bulls celebrate the momentum, while skeptics cite stretched valuation and upcoming share unlocks as risks.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A high-volume breakout has drawn attention, with traders linking optimism to Michael Caputos appointment to the Presidents Cancer Panel and speculating it could support broader access to ImmunityBios Anktiva; no such access change is confirmed. The community is also debating whether heavy short interest could amplify the move or whether the rally is momentum-driven without a new company announcement.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Vaccine-sector optimism around reports of a suspected pneumonic-plague outbreak in Russia, alongside a rivals positive late-stage vaccine results, is driving attention to NVAX. Traders debate whether the move is outbreak-related FOMO or reflects Novavaxs partner-led vaccine rollout and could fuel a short squeeze; others caution that Novavax has no plague vaccine and the outbreak claims remain uncertain.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

A sharp rebound and technical breakout have put DNA in focus, with traders tying the move to renewed interest in Ginkgos autonomous-lab and AI-biology strategy, including its Cloud Lab and OpenAI-related developments. Bulls see a potential re-rating, while skeptics question whether the partnerships and lab automation can translate into meaningful revenue amid the companys weak financial track record.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Vaxcyte shares are drawing attention after VAX-31 met the primary endpoints in its pivotal Phase 3 trial, strengthening the candidates prospects against established pneumococcal vaccines. Traders are also weighing the bullish clinical results against the dilutive impact of the announced equity and convertible-note offerings, with some noting the stock has held up despite the financing news.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

A reported suspected pneumonic-plague death at a Russian research institute has traders connecting EBSs biodefense portfolio to potential renewed demand for medical countermeasures. The incidents cause remains disputed, and the move is also prompting speculation about heavy-volume buying and a possible short squeeze.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias push to fresh highs and a breakout above recent resistance is driving attention, alongside broader enthusiasm for AI and chip stocks. Bulls point to continued AI-infrastructure demand, while skeptics warn of stretched valuations, rising yields, light volume and possible profit-taking.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Upcoming quarterly results are the main focus, with traders debating whether the latest 75 MW at Polaris Forge 1 reaching ready-for-service and continued data-center expansion will support revenue and reassuring guidance. Bulls point to execution and contracted demand, while skeptics note the stocks weak performance and question whether even strong results can overcome financing and broader data-center sector pressures.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs breakout to fresh highs is drawing attention, with traders citing optimism around AI-chip demand and Elon Musks confirmation of preliminary discussions about TSMCs potential role in the Texas Terafab project. The partnership is not finalized, and while many traders see room for the rally to continue, others caution that momentum and volume may be stretched and flag profit-taking risk.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas planned Nasdaq-100 inclusion is drawing attention, with traders expecting index-tracking funds to buy shares and some attributing the rally to short covering. The move builds on optimism around the Merck-partnered melanoma vaccine trial, while bears argue the rally has outrun the companys fundamentals and valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate...

Aktis Oncology (AKTS) Expected to Announce Earnings on Friday

Aktis Oncology (NASDAQ:AKTS) will be releasing its Q1 2026 earnings on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-akoustis-technologies-inc-stock...

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - What's Next?

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Aktis Oncology (NASDAQ:AKTS) Stock Crosses Above Fifty Day Moving Average - Time to Sell...

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's  What You Should Know

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why

Aktis Oncology (NASDAQ:AKTS) Stock Price Down 3.7% - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five...

Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients...

HC Wainwright Comments on Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC...

Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

HC Wainwright boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a report on Tuesday...

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.46	--	--	N/A
Q2 '26	-$0.43	--	--	N/A
Q1 '26	-$0.37	--	--	N/A
Q4 '25	-$21.59	--	--	N/A
Q1 '25	-$0.07	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

AKTS Earnings

Upcoming Earnings: Q3 '26

Historical Earnings